Key Highlights

• DNA X (NASDAQ: SONM) completed a private sale of non-voting Series B Convertible Preferred Stock at a set price per share.

• The financing totals an aggregate offering price, split between cash proceeds and debt conversion.

• Funds will support working capital and corporate needs, with DNA Holdings Venture, linked to a board member, as the investor.

• The agreement grants registration rights for convertible shares and a one-year participation right in future offerings.

DNA X has successfully secured additional funding through a private placement backed by an insider-affiliated investor. The biotechnology company announced the closing of a transaction with DNA Holdings Venture, an entity connected to one of its directors, which provided capital through the issuance of preferred securities.

Deal Structure Breakdown

The company sold a specified number of shares of non-voting Series B Convertible Preferred Stock, par value $0.001 per share, at a purchase price of $6.00 per share. The total aggregate offering price consists of cash proceeds along with the cancellation of outstanding debt owed to the investor.

Investor Profile

DNA Holdings Venture, which qualifies as a holder of more than 5% of the company’s outstanding stock, is associated with Scott Walker, a member of DNA X’s board of directors. As part of the agreement, the investor obtained registration rights for shares that may later convert into common stock, facilitating potential future liquidity.

Use of Proceeds

Proceeds from the offering are earmarked for working capital and general corporate purposes. The terms of the deal include restrictions on additional securities issuances until stockholders approve the conversion of the preferred shares into common stock.

Conversion Terms

The Series B Preferred Stock will carry a stated value per share and is designed to convert into common stock, par value $0.001 per share, pending stockholder approval. Until such approval is obtained, the preferred shares will not be convertible, and no public market for them currently exists.

Registration Commitments

DNA X is required to file a resale registration statement within a set period following stockholder approval. The company has committed to maintaining the effectiveness of this filing until all convertible shares are sold, with provisions for liquidated damages if deadlines are not met.

Future Financing Rights

Under the agreement, DNA Holdings Venture gains the right to participate in future equity or debt financings for a defined period, subject to a participation cap. The transaction also includes standard representations, warranties, and indemnification clauses.

Advisory Agreement

At the closing of the private placement, DNA X anticipates finalizing a consulting arrangement with DNA Holdings Venture, Scott Walker, and Brock Pierce. The agreement involves the issuance of common shares as compensation for advisory and development services related to the company’s strategic initiatives. Corporate filings, including the relevant exhibits, have been submitted to regulatory authorities to formalize these arrangements.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.